Galmed Pharmaceuticals Ltd
GLMD
Market Cap$2.8M
Close$
$1.06
17.1% downside
Current Fair Value
17.1% downsideOvervalued by 17.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.80 Million |
|---|---|
| Enterprise Value | $-1,852,043.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-8.08 |
| Beta | 0.49 |
| Outstanding Shares | 1,664,884 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.27 |
|---|---|
| PEG | -0.92 |
| Price to Sales | - |
| Price to Book Ratio | 0.14 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.27 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Galmed Pharmaceuticals Ltd
CEO: Allen Baharaff Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is ...